Pathstone Holdings
PTCT icon

Pathstone Holdings’s PTC Therapeutics PTCT Stock Holding History

Pathstone Holdings’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.53M Buy
31,023
+8,539
+38% +$617K 0.01% 984
2026
Q1 		$1.53M Buy
22,484
+15,727
+233% +$1.11M 0.01% 1180
2025
Q4 		$513K Buy
6,757
+872
+15% +$63.4K ﹤0.01% 1740
2025
Q3 		$361K Buy
5,885
+67
+1% +$3.49K ﹤0.01% 1935
2025
Q2 		$284K Sell
5,818
-286
-5% -$13.6K ﹤0.01% 1944
2025
Q1 		$311K Buy
6,104
+163
+3% +$8.13K ﹤0.01% 1923
2024
Q4 		$268K Sell
5,941
-1,027
-15% -$44K ﹤0.01% 2013
2024
Q3 		$259K Sell
6,968
-384
-5% -$12.9K ﹤0.01% 2046
2024
Q2 		$225K Buy
+7,352
New +$238K ﹤0.01% 2094

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Pathstone Holdings's PTCT Position: Q2 2026 in Review

Pathstone Holdings increased its PTC Therapeutics (PTCT) stake by 38% in Q2 2026, buying an estimated $617K and bringing the position to 31,023 shares worth $2.53M. The position accounts for 0.01% of the portfolio, ranked #984.

Pathstone Holdings first reported a position in PTCT in Q2 2024 and has held it in 9 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Pathstone Holdings held 31,023 shares of PTC Therapeutics worth $2.53M as of Q2 2026.
  • Pathstone Holdings bought 8,539 PTC Therapeutics shares in Q2 2026, an estimated $617K.
  • PTC Therapeutics made up 0.01% of Pathstone Holdings's portfolio in Q2 2026, its #984 holding.
  • Pathstone Holdings first reported a position in PTC Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.